A similar mechanism was pointed out for the pan-RAF inhibitor L-779,450: co-treatment with soluble TRAIL has been recently shown to overcome TRAIL resistance of both BRAF-mutant and BRAFwt melanoma cells by increasing apoptosis through release of cytochrome c and Smac/DIABLO from mitochondria and augmented activation of Bax and Bim. Here, BCL2L11 is linked to melanoma.